Highbridge Capital Management’s AbbVie ABBV Stock Holding History

Highbridge Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,200	Closed	-$296K	–	466
2018 Q2	$296K	Buy	+3,200	New	+$313K	0.01%	705
2018 Q1	–	Sell	-20,300	Closed	-$1.96M	–	1130
2017 Q4	$1.96M	Buy	20,300 +8,900	+78%	+$839K	0.04%	395
2017 Q3	$1.01M	Buy	+11,400	New	+$868K	0.02%	590
2017 Q2	–	Sell	-8,100	Closed	-$529K	–	1193
2017 Q1	$529K	Sell	8,100 -6,300	-44%	-$396K	0.01%	872
2016 Q4	$902K	Buy	14,400 +6,600	+85%	+$403K	0.02%	568
2016 Q3	$493K	Buy	+7,800	New	+$505K	0.01%	790
2016 Q1	–	Sell	-15,500	Closed	-$918K	–	1434
2015 Q4	$918K	Buy	+15,500	New	+$893K	0.01%	786
2015 Q3	–	Sell	-4,700	Closed	-$316K	–	1479
2015 Q2	$316K	Sell	4,700 -9,000	-66%	-$588K	﹤0.01%	1129
2015 Q1	$802K	Buy	+13,700	New	+$828K	0.01%	819

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Highbridge Capital Management's ABBV Position: Q3 2018 in Review

Highbridge Capital Management sold out of AbbVie (ABBV) in Q3 2018, closing a stake of 71,495 shares — an estimated $6.62M sold.

Highbridge Capital Management first reported a position in ABBV in Q2 2013 and held it in 17 quarters. The position peaked at $71.2M in Q1 2015. 1,957 funds tracked by Wall St. Rank hold ABBV as of Q3 2018.

Highbridge Capital Management reported no remaining AbbVie position as of Q3 2018 after selling out during the quarter.
Highbridge Capital Management sold 71,495 AbbVie shares in Q3 2018, an estimated $6.62M.
Highbridge Capital Management first reported a position in AbbVie in Q2 2013 and held it in 17 quarters.
Highbridge Capital Management's AbbVie position peaked at $71.2M in Q1 2015.
1,957 funds tracked by Wall St. Rank held AbbVie as of Q3 2018.

Based on Highbridge Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.